In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus
- PMID: 9302441
- DOI: 10.1097/00002030-199711000-00006
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus
Abstract
Objective: Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8, has been implicated as the causative agent of Kaposi's sarcoma. Retrospective studies show that the risk of development of Kaposi's sarcoma is significantly lower in AIDS patients who received ganciclovir or phosphonoformic acid (PFA) therapy. Therefore, in vitro antiviral drug sensitivity of KSHV was studied.
Methods: The KSHV genome is a latent episome in lymphoma cells such as the BCBL-1 cell line. Lytic KSHV DNA synthesis is induced by the phorbol ester 12-O-tetradecanoyl phorbol-13-acetate in BCBL-1 cells; this system was used to evaluate the effects of antiviral drugs on KSHV DNA synthesis.
Results: Linear (lytic) KSHV DNA synthesis and virus secretion was inhibited in BCBL-1 cell cultures by cidofovir (median inhibitory concentration, 0.05 microM), ganciclovir (5.1 microM) and PFA (97 microM), and by aciclovir (75 microM). Prolonged incubation of BCBL-1 cells with antiviral drugs had no effect on episomal KSHV DNA synthesis.
Conclusions: The antiviral drug assay developed shows that KSHV is very sensitive to cidofovir, moderately sensitive to ganciclovir and PFA, and weakly sensitive to aciclovir. Therefore, low doses of cidofovir, or high doses of PFA or ganciclovir could suppress clinical reactivation of KSHV. Antiviral drugs did not inhibit episomal virus DNA synthesis, suggesting that the latent form of viral DNA is replicated by host DNA polymerases. Consequently, no benefit can be expected from antiviral drugs in KSHV-positive B-cell lymphomas or during latency.
Similar articles
-
Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication.J Virol. 2002 May;76(10):5208-19. doi: 10.1128/jvi.76.10.5208-5219.2002. J Virol. 2002. PMID: 11967335 Free PMC article.
-
Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.J Clin Invest. 1997 May 1;99(9):2082-6. doi: 10.1172/JCI119380. J Clin Invest. 1997. PMID: 9151779 Free PMC article.
-
Potent antiviral activity of north-methanocarbathymidine against Kaposi's sarcoma-associated herpesvirus.Antimicrob Agents Chemother. 2005 Dec;49(12):4965-73. doi: 10.1128/AAC.49.12.4965-4973.2005. Antimicrob Agents Chemother. 2005. PMID: 16304159 Free PMC article.
-
Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.J Hosp Infect. 1996 Aug;33(4):235-48. doi: 10.1016/s0195-6701(96)90010-9. J Hosp Infect. 1996. PMID: 8864937 Review.
-
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].Nihon Rinsho. 1998 Jan;56(1):140-4. Nihon Rinsho. 1998. PMID: 9465679 Review. Japanese.
Cited by
-
Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection.J Virol. 2006 Oct;80(20):10073-82. doi: 10.1128/JVI.01156-06. J Virol. 2006. PMID: 17005685 Free PMC article.
-
Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.Antiviral Res. 2007 Jan;73(1):12-23. doi: 10.1016/j.antiviral.2006.05.017. Epub 2006 Jun 14. Antiviral Res. 2007. PMID: 16842866 Free PMC article.
-
Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication.J Virol. 2002 May;76(10):5208-19. doi: 10.1128/jvi.76.10.5208-5219.2002. J Virol. 2002. PMID: 11967335 Free PMC article.
-
Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.Cancers (Basel). 2022 Jan 18;14(3):484. doi: 10.3390/cancers14030484. Cancers (Basel). 2022. PMID: 35158752 Free PMC article. Review.
-
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.J Infect Dis. 2008 Jul 1;198(1):23-30. doi: 10.1086/588820. J Infect Dis. 2008. PMID: 18491970 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical